Pfizer will pay its 352nd consecutive quarterly dividend on Dec. 7, 2026.
A patent cliff, a cash-draining acquisition, and major clinical setbacks could threaten the dividend, but all three would likely need to happen to end it.
Pfizer is more likely to navigate the patent cliff and keep funding its dividend at current levels.
Pfizer (NYSE: PFE) shareholders should mark Dec. 7, 2026, on their calendars. The giant drugmaker is scheduled to pay its 352nd consecutive quarterly dividend on that date.
That payout is a sure thing for investors who owned shares as of the close of business on Nov. 6, 2026. But what would it take to end Pfizer's impressive dividend streak?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
No company can continue paying dividends indefinitely without generating enough cash to fund operations while funding the dividend program. Pfizer's free cash flow currently covers its dividend payouts. However, the big pharma company faces a patent cliff that could upset the status quo.
But Pfizer has a cushion that could allow it to pay quarterly dividends even if its free cash flow declines sharply. The drugmaker sits atop a cash stockpile of $14.3 billion (including cash, cash equivalents, and short-term investments). That's enough to fund dividends for well over a year. If Pfizer uses a big chunk of its cash to finance an acquisition, though, this cushion could disappear.
Importantly, Pfizer is counting on its newer drugs and promising late-stage pipeline candidates to help it successfully navigate the patent cliff. Multiple major clinical setbacks could cause management to reevaluate the company's growth prospects and potentially realize that continuing to pay dividends isn't viable.
It isn't too far-fetched to envision one of these scenarios causing Pfizer to cut its dividend. However, A reduced dividend would still keep the streak alive. I think that all three scenarios would have to unfold for Pfizer to eliminate its dividend.
Could this triple-whammy for Pfizer happen? It's possible, but not probable. In my view, Pfizer is much more likely to navigate the looming patent cliff relatively well, while continuing to generate sufficient free cash flow to fund the dividend at current levels. This big pharma stock should remain an attractive alternative for investors seeking higher income.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 19, 2026.
Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.